BioCentury | Aug 28, 2020
Emerging Company Profile

Concarlo: targeting proliferation and resistance in one go

...HER-negative advanced or metastatic breast cancer: Ibrance palbociclib...
BioCentury | Jun 17, 2020
Product Development

Data in early breast cancer recurrence point to larger market for Lilly’s Verzenio

...CDK6 inhibitor, one that was recently made clearer by the failure of Pfizer’s CDK4/6 inhibitor Ibrance...
...in the monarchE trial. Detailed data weren’t disclosed. Of the three approved CDK4/6 inhibitors, Ibrance palbociclib...
...by far the leader in sales. Pfizer Inc. (NYSE:PFE) reported about $5 billion globally in Ibrance...
BioCentury | Jun 1, 2020
Product Development

Ibrance failure in adjuvant breast cancer opens door for Novartis, Lilly

...NYSE:LLY). Pfizer Inc. (NYSE:PFE) said late Friday that the Phase III PALLAS trial of Ibrance palbociclib...
...Ibrance in other solid tumors, largely in different combination settings. The pharma is also testing Ibrance...
...Epidermal growth factor receptor 2 Stephen Hansen, Associate Editor Ibrance (Brand), PD-0332991 (Compound #), palbociclib (Generic), Ibrance...
BioCentury | Jan 28, 2020
Company News

Bourla chooses BD over buybacks in 2020

...of breast cancer drug Ibrance palbociclib, cardiovascular therapy Eliquis apixaban and autoimmune therapy Xeljanz tofacitinib. Ibrance...
BioCentury | Jan 2, 2020
Politics & Policy

Drug price hikes would have been impossible under pending bipartisan legislation backed by White House, Democrats

...are rebated. 2020 price increases include a 5% rise in Pfizer’s breast cancer drug Ibrance palbociclib...
BioCentury | Dec 10, 2019
Emerging Company Profile

Zentalis debuts with trio of clinical oncology programs, $85M series C

...an oral selective estrogen receptor degrader (SERD) in Phase I/II testing in combination with Ibrance palbociclib...
...fulvestrant, for hormone receptor-positive breast cancers, including HER2-negative tumors, as monotherapy and in combination with Ibrance...
BioCentury | Nov 22, 2019
Finance

Syncona backs Cambridge oncology spinout Azeria in £32M series B

...for other approaches. Three CDK4/CDK6 inhibitors are approved in post-progression settings following endocrine therapy: Ibrance palbociclib...
BioCentury | Nov 21, 2019
Clinical News

Syncona backs Cambridge oncology spinout Azeria in £32M series B

...for other approaches. Three CDK4/CDK6 inhibitors are approved in post-progression settings following endocrine therapy: Ibrance palbociclib...
BioCentury | Nov 18, 2019

Ibrance boosts effect of HIF2A inhibition in renal cancer

...Jr., a winner of this year's Nobel Prize in Physiology or Medicine, showed that Ibrance palbociclib...
...inhibition in clear cell renal cell carcinoma (ccRCC). In a panel of human ccRCC lines, Ibrance...
...Jr., Harvard Medical School, Boston, Mass. email: william_kaelin@dfci.harvard.edu Claire Quang Ibrance (Brand), PD-0332991 (Compound #), palbociclib (Generic), Ibrance...
BioCentury | Sep 17, 2019
Company News

Sept. 13 Company Quick Takes: FDA issues warning on CDK4/6 drugs; plus Castle Creek to buy Fibrocell and Eidos rebuffs BridgeBio

...said included fatalities, though no numbers were disclosed. The warning includes marketed CDK4/6 inhibitors Ibrance palbociclib...
Items per page:
1 - 10 of 141